NEO · Neogenomics Inc
Market Cap
$2.23B
Shares
128.48M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.32
Open$17.85
Day$17.21–17.92
52W close$7.19–18.64
Avg vol 30d1.8M
Short int15.8M · 12.3% float · 9.0d
Short vol71%
Last earningsJul 28, 2026
DataJan 2020–Sep 2026
Filing10-Q · Jul 28
Up next
Next earnings call
Oct 27, 2026
Est · unconfirmed
· in 6 wks
filed Jul 28, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$766.29M
Trailing 12 months
Net income (TTM)
−$51.88M
Trailing 12 months
Revenue growth YoY
+11.2%
Year over year
Operating margin
-8.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-0.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.3%
Year over year · more shares
Price change (1Y)
+107.7%
Trailing year
Short interest
12.3%
Latest settlement · 9.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+47%
above
Price vs 50-day avg
+9%
above
RSI (14)
56
neutral
MACD trend
Negative
52-week position
88%
near high
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+118%
trailing
YTD return
+47%
this year
Relative strength
+100%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $16 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +58 funds added
Insider flow
Distributing
Net -$321.4K over 90 days · 100% sells
Short interest
Falling
12.27% of float · ▼ -0.8% MoM · 9.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
269 holders — mid 3-yr range
Squeeze score
78
high risk · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
Gross margin
43%
contracting
EPS growth
−300%
Y/Y
Free cash flow
$-21.8M
Balance sheet
$195.7M
net debt
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−46%
past year
ATR
4.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jun 30, 2026
Full year 26 revenue
· full year 2026
Initiated
$802M – $806M
prior FY $727.33M
midpoint +10.5% Y/Y
Prior guidance
period ended
· from the Earnings Call filed Dec 31, 2021
Revenue
· full year
$530M – $550M
Revenue
· Q1
$118M – $120M
Amortization
· 2022
$34M
Depreciation
· 2022
$38M
Guided vs delivered
· last 3 settled
Revenue
full year
guided $530M – $550M
$509.73M
Miss −5.6%
Revenue
Q1
guided $118M – $120M
$117.17M
Miss −1.5%
Consolidated revenue
full-year 2021
guided $482.5M – $487.5M
$484.33M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+47%
Bullish
Price vs 50-day avg
+9%
Bullish
RSI (14)
56
Neutral
MACD trend
Negative
Bearish
52-week position
88%
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $16 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +58 funds added
Insider flow
Distributing
Net -$321.4K over 90 days · 100% sells
Short interest
Falling
12.27% of float · ▼ -0.8% MoM · 9.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
269 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7
Now $17 · 88%
Range high $19
vs 200-day avg +47%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NEO
this stock
Neogenomics Inc
|
$2.23B | +47.3% | +10.1% | — | 12.3% |
|
TMO
Thermo Fisher Scientific Inc.
|
$225.48B | +5.2% | +14.5% | 32.8 | 1.5% |
|
DHR
Danaher Corp /De/
|
$140.70B | -12.6% | +8.5% | 35.5 | 1.4% |
|
NTRA
Natera, Inc.
|
$47.41B | +43.6% | -2.8% | — | 3.8% |
|
IQV
Iqvia Holdings Inc.
|
$43.69B | +16.1% | +41.6% | 32.5 | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NEO | -0.8% | +5.7% | +117.6% | -3.3% | +47.3% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +0.4% | +7.4% | +99.8% | -2.9% | +35.2% |
Key facts
CIK
1077183
CUSIP
64049M209
13F (30d)
71 filings
71 filers
Visit website
Investor relations